ArticleBMC nephrology2025
MicroRNA-107 alleviates ferroptosis-mediated acute kidney injury by regulating the PI3K/Akt/mTOR pathway.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endocan attenuates LPS-induced alveolar type II cells injury through PI3K/Akt/mTOR pathway.Upsala journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMechanistic pathways and biomarkers need to be explored to elucidate the pathogenesis of acute kidney injury (AKI). This study examined miR-107 expression in AKI and the molecular mechanisms underlying the regulation of ferroptosis-mediated AKI.
methodsThis study included 30 patients with AKI and 30 healthy individuals in the control group. The miR-107 serum expression levels were determined using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). The HK-2 cells were subjected to ferroptosis in vitro, and a AKI mice model to study the effect of miR-107 in vivo. After RNA overexpression, malondialdehyde (MDA), lipid reactive oxygen species (ROS), and glutathione (GSH) levels were measured. Additionally, the regulatory relationship between miR-107 and its downstream pathway genes was analyzed.
resultsThe down-regulated expression of miR-107 detected in the serum of patients with AKI suggested its utility as a potential diagnostic indicator for AKI. Moreover, miR-107 expression was down-regulated in both HK-2 cell models of AKI and HK-2 cell ferroptosis model. Upregulation of miR-107 decreased MDA expression and increased GSH expression in erastin (Era)-induced ferroptosis in HK-2 cells in vitro. Additional, AKI mice exhibited down-regulated expression levels of miR-107, and the ROS, MDA, and GSH expression changes in AKI mice were rescued after miR-107 overexpressed, which was consistent with the effect of Fer-1 treatment. Furthermore, the PI3K/Akt/mTOR pathway exhibited a correlation with miR-107 expression in Era-induced ferroptosis in HK-2 cells.
conclusionIn summary, miR-107 is expressed at low levels in AKI and can inhibit ferroptosis in HK-2 cells, which may play a protective role against AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.